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Abstract
Antibiotics increase the frequency of resistant bacteria by providing them a competitive advantage over sensitive strains.
Here, we develop a versatile assay for differential chemical inhibition of competing microbial strains, and use it to identify
compounds that preferentially inhibit tetracycline-resistant relative to sensitive bacteria, thus ‘‘inverting’’ selection for
resistance. Our assay distinguishes compounds selecting directly against specific resistance mechanisms and compounds
whose selection against resistance is based on their physiological interaction with tetracycline and is more general with
respect to resistance mechanism. A pilot screen indicates that both types of selection-inverting compounds are secreted by
soil microbes, suggesting that nature has evolved a repertoire of chemicals that counteracts antibiotic resistance. Finally, we
show that our assay can more generally permit simple, direct screening for drugs based on their differential activity against
different strains or targets.
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Introduction
Treatments with antibiotics are intrinsically selective processes.
While antibiotics are primarily chosen based on their absolute effect on
target pathogens, they also strongly affect the relative competitive
advantage of drug resistant versus sensitive strains. As a result, use of an
antibiotic promotes the emergence and spread of strains resistant to it.
In the face of a decline in discovery of new antibacterials, the rise of
these resistant strains has led to an acute emerging health concern [1].
While an antibiotic confers a strong selective advantage on bacteria
resistant to it, certain compounds exist that can reduce or even invert
this advantage. For example, compounds which disable resistance
mechanisms, such as inhibitors of drug-degrading enzymes or of
efflux pumps can neutralize the advantage of resistance [2,3]. Other
compounds can go even further by completely inverting this selective
advantage, causing the resistant bacteria to lose in competition with
their sensitive cousins. Such selection-inverting compounds can be
classified into two types. First, selection against a specific resistance
mechanism can occur when this mechanism also operates to enhance
thetoxicity of certaincompounds [4,5] (e.g., tetracycline efflux pumps
increase sensitivity of Escherichia coli to fusaric acid) [6]. Such
mechanism-mediated selection against resistance is often termed
‘negative cross-resistance’ or ‘collateral sensitivity’ [7]. Second, we
have recently shown that inversion of selection can occur when the
antibiotic to which the bacteria are resistant is combined with a toxin
whose potency is suppressed by the antibiotic [8,9]. Since resistance
effectively eliminates the antibiotic, it removes not only the particular
inhibitory effect of the antibiotic, but also removes the protection
from the toxin provided by the antibiotic. Where the latter effect is
greater, the result is a net reduction in the fitness of the resistant
relative to the sensitive strain (e.g., inhibition by ciprofloxacin is
suppressed by tetracycline and their combination can select against
tetracycline resistance) [8]. Since this second class of selection-
inverting compounds do not directly select against resistance genes,
but instead select on the physiological consequences of the reduced
antibiotic effect that the genes bring about, we say that the resulting
selection is ‘‘potentiated’’ by the resisted antibiotic. Since selection
inversion by the first class is mediated by the resistance genes alone,
without requiring the presence of the drug to which the bacteria are
resistant, we refer to it as ‘‘direct’’.
Motivated by the examples of compounds known to exert direct
or potentiated selection against resistance, we asked how common
such compounds are and devised a general strategy to screen for
them. By combining competition between fluorescently labeled
bacterial strains with a robust test of bacterial drug susceptibility,
we have produced a simple and flexible assay which allows
visualization of both the absolute inhibitory effect of compounds as
well as the differential selection that they impose on strains
sensitive and resistant to a chosen antibiotic.
Results
Our method is based on the agar diffusion assay for identifying
the anti-microbial effect of compounds [10]. In this classical assay,
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nutrient agar plate. Compounds to be tested are spotted locally on
the agar surface. The plates are incubated and the cells grow as the
test compounds diffuse outwards. Inhibitory compounds create
zones of inhibition in the grown microbial lawn, where Minimal
Inhibitory Concentrations (MICs) of the drugs were reached
before the cells grew to detectable levels. The diameter of the
inhibition zone reflects the susceptibility of the test organism
(Figure 1A). The simple, inexpensive nature of the agar-diffusion
assay, its wide dynamic range for effective drug concentrations,
and compatibility with many organisms, has led to its extensive use
in drug discovery and clinical diagnostics.
Building on this well-established technique, we developed a
competition-based method for detecting the differential impact of
compounds on the selective advantage of resistance. By competing
two fluorescently labeled strains on the agar, we are able to
observe not only absolute zones of inhibition, but also ‘‘zones of
selection’’ in which compounds modulate the ratio between the
strains (Figure 1B). Briefly, we mix drug-sensitive and drug-
resistant strains, differentially labeled with constitutively-expressed
Cyan and Yellow Fluorescent Protein (CFP, YFP) at 1:1 ratio, and
seed them onto nutrient agar plates (Figure 1B). We then spot test
compounds onto the plates and incubate overnight. By imaging
the grown-out plates for each fluorophore using a fluorescent plate
imager (See Materials and Methods), we obtain the final ratios
between the strains across the entire plate (Figure S1). Where the
strains are not inhibited or are equally affected by a compound,
the final ratio between the strains shows little change (yellow).
However, compounds which differentially inhibit the sensitive and
resistant strains generate inhibition zones with different diameters
and thus a ring-shaped zone of selection between them where only
one of the strains has grown (Figure 1B). While an antibiotic
Figure 1. Competition-based agar diffusion assay for compounds that select against antibiotic resistance. A, A classical diffusion assay
challenges a growing lawn of target bacterial cells (grey) with test compounds that diffuse from localized spots (white dots) on a nutrient agar plate.
The size of the zones where bacterial growth is inhibited (dark region) reflects the potency of the compounds against the target strain. Non-inhibitory
compounds or compounds to which the cells are resistant yield little or no zone of inhibition. Close-ups illustrate cellular growth across the plate.
B, In the assay for differential selection, a pair of fluorescently-labeled strains, one drug-sensitive (YFP, shown in green) and one resistant (CFP, shown
in red), are mixed in equal proportions, spread on nutrient agar and challenged with diffusing compounds. Fluorescent imaging yields ratios of the
densities of the two strains across the plate. Non-selective conditions maintain the strains at 1:1 ratio (yellow), while compounds with different
relative effect on the sensitive and resistant strains yield concentric zones of inhibition with different diameters resulting in a strongly dominant strain
in the ‘‘zone of selection’’ between them (red or green rings). Selection by a drug for resistance to itself appears as a red ring, while a compound
which selects against resistance is encircled by a green ring. Schematic close-ups illustrate cellular growth of the sensitive and resistant strains across
the plate. C, Tetracycline-resistant (CFP-labeled strain t17cl, shown in red), and sensitive (YFP-labeled strain Wyl, shown in green) E. coli are mixed in
equal proportions and spread over nutrient agar (Anhydrotetracycline in the agar induces expression of tetracycline resistance without inhibiting
either strain; see Materials and Methods). Doxycycline generates strong selection for the tetracycline resistant strain (DOX, red ring), while fusaric acid
selects for tetracycline sensitivity (FSR, green ring), and ciprofloxacin does not select, but inhibits the strains equally (CPR, no ring).
doi:10.1371/journal.pone.0015179.g001
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it (Figure 1B, red ring), selection inverters, which give the sensitive
strain an advantage, generate a ring of the opposite color
(Figure 1B, green ring). Therefore, unlike the classical diffusion
assay which reports on the absolute antimicrobial effect of a
compound, the assay we developed is sensitive to the differential
effect of compounds on competing microbial strains. We note
though, that deviations from the truncation selection depicted in
Figure 1 may complicate interpretation of the results and such
analysis is beyond the scope of this paper.
We demonstrate our differential assay by focusing on resistance
to tetracyclines, a generally safe, inexpensive, widely available,
broad spectrum class of antibiotics whose overuse in both clinical
and agricultural contexts has led to crippling levels of clinical
resistance [11]. Tetracycline resistance is commonly due to the
tetA-tetR operon, encoding the TetA efflux pump and the TetR
repressor of pump expression in the absence of tetracyclines. We
use a pair of E. coli strains with the same genetic background, with
one sensitive to tetracyclines (labeled with YFP, shown in green),
and the other carrying a chromosomally integrated cassette
containing the tetA-tetR tetracycline resistance operon (labeled
with CFP, shown in red; ‘dye swap’ controls using strains with the
fluorescent labels reversed were also performed). Using these
strains, our differential assay readily identified selection for
tetracycline resistance by doxycycline (DOX, Figure 1C, red
ring), and selection against resistance by fusaric acid (FSR,
Figure 1C, green ring [6].
The assay can be performed in the absence or in the presence of
background selection by tetracycline, permitting identification and
discrimination of compounds exerting direct or potentiated
selection on resistance. In the absence of background selection by
tetracycline (Type I Assay), the drug-sensitive and -resistant cells
differ only in their expression of the resistance genes (induced by
anhydrotetracycline in the agar at levels which do not affect growth;
see Materials and Methods). Therefore, this assay is specific to
‘direct’ selection for and against resistance. Such direct selection is
exhibited by doxycycline and fusaric acid, but not by ciprofloxacin
or erythromycin (Figures 1C, 2A, ‘‘Type I Assay’’). To reveal
potentiated selection on tetracycline resistance, the same chemicals
are assayed with a small quantity of doxycycline in the agar
(generating ,10% background growth inhibition of the sensitive
relative to the resistant strain; Figure 2A, ‘‘Type II Assay’’; see
Materials and Methods). We find that the uniform background level
of doxycycline potentiates selection by ciprofloxacin against
tetracycline resistance (Figure 2A, Type II, CPR, green ring) and
by erythromycin in favor of tetracycline resistance (Figure 2A, Type
II, ERY, red ring). This observation is consistent with the
suppressive versus synergistic interactions of doxycycline with
ciprofloxacin and erythromycin, respectively. Since doxycycline
suppressestheeffectofciprofloxacin[8,12],itsbackgroundpresence
decreases the radius of the ciprofloxacin inhibition zone of the tet
S
strains. However, the tet
R strain, which pumps doxycycline out of
the cell, does not enjoy this protection from ciprofloxacin and is
thereby selected against. Conversely, since tetracycline and
erythromycin interact synergistically, erythromycin potency is
enhanced against the tet
S, but not against the tet
R strain, resulting
in relative selection for tetracycline resistance. This ‘Type II’ assay,
in which the antibiotic to which the bacteria are resistant is added
uniformly to the agar, therefore exposes potentiated, interaction-
mediated, selection for and against resistance.
Together, the two assays comprise a simple means of identifying
novel selection-inverting compounds and classifying them as
exerting direct or potentiated selection on resistance (Figure 2A).
An interesting prediction is that direct selection, which acts on
specific resistance mechanism, will be exclusive to strains bearing
this, but not other, resistance mechanism. On the other hand,
potentiated selection on resistance, which occurs via selection on
the consequences of reduced antibiotic effect generally conferred
by resistance, should be insensitive to the particular resistance
mechanism [8,9].
To test this prediction and the generality of selection inversion
with respect to mechanism of resistance, we applied our assay to
another pair of strains, in which tetracycline resistance is mediated
by a different mechanism. Specifically, we replaced the tetA
tetracycline efflux pump with tet(36) which confers resistance to
tetracyclines through a ribosomal protection mechanism [13]. We
observe that tetracycline-potentiated selection inversion by
ciprofloxacin indeed works on both of these very distinct resistance
mechanisms, while direct selection inversion by fusaric acid is
specific to the efflux-pump bearing microbes (Figure 2B).
Interestingly, the direct selection inverter fusaric acid is a
natural product of microorganisms found on crops and in soil [14].
Other compounds produced by soil organisms are also known to
reduce or invert the selective advantage of resistance [2,4]. Since
soil microbes are a rich source of antimicrobial compounds, the
coexistence of resistant and sensitive species in the soil [15] may
suggest a role for natural compounds which can act to invert
selection for resistance. Motivated by these ideas, we set up our
assay to search for soil species which produce chemical compounds
that invert selection for antibiotic resistance.
We screened microbial isolates from diverse soil samples for
production of compounds that invert selection for tetracycline
resistance (Figure 3). Since soil microbes grow at varying rates and
produce secondary metabolites at varying times, and because their
isolation media is often different from our E. coli competition media,
we decoupled the isolate growth and compound production phase
of the assay from the resistant-sensitive competition phase. We first
allow the isolates to grow and secrete compounds for up to two
weeks under various culture conditions and only then apply our
diffusion-based competition assay using two complementary
methods: an ‘‘overlay assay’’ which is fast but crude, and a ‘‘plug
assay’’ which is more elaborate, but less biased. In the ‘‘overlay
assay’’, we cover plates bearing mixed colonies of microbes
extracted from soil samples with top agar containing a mixture of
our labeled tetracycline-sensitive and resistant assay strains, fresh
nutrients, and a small amount of doxycycline for background
tetracycline selection. After incubation and imaging, rings of
selection are found around colonies of faster growing soil microbes
which have rapidly secreted compounds selecting on tetracycline
resistance (Figure 3A). In the ‘‘plug assay’’, we re-streak individual
soil colonies on separate plates. Plugs of their conditioned agar are
then transferred to holes in fresh assay plates spread with our test
strain pair [16]. Similar to pure compounds spotted on the plates,
secreted compounds diffuse fromthe plugs and some create zones of
selection against resistance (Figure 3B, S2).
We have screened more than 1000 soil isolates for production of
compounds that show differential selection on tetracycline
resistance. Even this modest screen identified several isolates that
excrete chemicals which bias selection in favor of sensitivity (6
isolates with stronger, and 16 with lesser effect). Interestingly, this
number was not very different than the number of isolates with
secretions that increase selection in favor of resistance (14 isolates
with stronger and 8 with lesser effect). Furthermore, using our
classification methodology (Figure 3C), we find that the majority of
these compounds exhibit potentiated rather than direct selection
on resistance (,90% of the compounds show a zone of selection
only in the presence of small amount of a tetracycline, Assay Type
II). These results suggest that production of selection inverting
Screen for Selection Inverters
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tetracyclines, even at sub-MIC levels can potentiate strong
selective pressure, both for and against resistance, by other
secreted compounds.
Discussion
In summary, we developed a sensitive differential assay for
compounds that select against antibiotic resistance. This assay is
Figure 2. Assay discriminates two principal types of selection on antibiotic resistance: Direct and Potentiated. A, Tetracycline-resistant
(tet
R, CFP-labeled, strain t17cl, shown in red) and sensitive (tet
S, YFP-labeled strain Wyl, shown in green) E. coli are mixed in equal proportions, seeded
onto agar, and challenged with one of four compounds: fusaric acid (FSR), ciprofloxacin (CPR), doxycycline (DOX), erythromycin (ERY). The assay is
performed either without (Type I Assay, Left), or with (Type II Assay, Right) background selection by doxycycline, which is added to the agar at a
uniform concentration that imposes a slight (,10%) growth inhibition of the sensitive strain (In Type I Assays, doxycycline is replaced by
anhydrotetracycline at a uniform concentration that does not inhibit either strain, but assures expression of the tetA efflux pump). Selection patterns
in Type I and II Assays classify compounds as selecting for or against tetracycline resistance (red, green) either directly (independently of background
doxycycline selection, Assay I) or via potentiation (requiring background doxycycline selection, Assay II only). B, Direct and potentiated selection-
inverters differ in their specificity with respect to the mechanism of resistance. This is illustrated by assay of selection inversion against a principal pair
of mechanisms (White, in schematic) that protect ribosomes (Blue) from attack by tetracyclines (Yellow diamonds). Direct selection by fusaric acid is
effective specifically against tetracycline resistance mediated by efflux pumps (tetA-bearing strain t17cl), but not against ribosomal protection (tet36-
bearing strain GB(c)) in Type I Assays (Left). In contrast, ciprofloxacin exerts potentiated, general, selection against tetracycline resistance regardless of
mechanism (Type II Assay, right).
doi:10.1371/journal.pone.0015179.g002
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S1, Methods S1), to resistance to other antibiotics and in other
microbial species (Figure S5), and even to screen for drug
specificity to pathogen versus human target isoforms (Figure S6,
Methods S1) [17]. A similar chromogenic technique has also
recently been used for sensitive biological detection of low levels of
Figure 3. Screen of soil isolates for production of compounds that select against tetracycline resistance. Microbes extracted from soil
are cultured on agar plates and then assayed for secretion of selection-inverters by (A) overlaying the mixed colony plates (left panel and zoom) with
top agar containing tetracycline-resistant (red, CFP-labeled strain t17cl), and sensitive (green, YFP-labeled strain Wyl) E.coli, nutrients and a small
quantity of doxycycline for background selection (Type II Assay, background selection). Fluorescent imaging (right panel) following incubation
reveals colonies secreting compounds which diffused into the overlay leading to inhibition (clear zone) and selection inversion (green ring).
Alternatively, (B) 5 mm agar plugs conditioned by purified soil isolates are transferred to Type II Assay plates spread with the E.coli test strains (Figure
S2). Fluorescent imaging after incubation reveals selection inversion by secreted compounds in the plugs (green ring, top of plate in right panel).
Pure ciprofloxacin is used as a plate control (white dot). C, Type I (left panel) and Type II (right panel) assays performed on pairs of conditioned agar
plugs reveal whether selection inversion (green rings) by secreted compounds is direct (‘dir’, left panel), or potentiated (‘pot’, right panel). White dot
indicates ciprofloxacin control.
doi:10.1371/journal.pone.0015179.g003
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that production of inverters of selection for tetracycline resistance
appears to be relatively common amongst soil microbes, and that a
majority of our hits appear to bias selection against tetracycline
resistance only in the presence of some amount of a tetracycline.
The combination of compounds that select for and against
resistance may suggest further insights into the puzzling coexis-
tence of antibiotic-resistant and sensitive species in the wild
[15,19,20,21].
Materials and Methods
Strains
See table of strains (Table S1).
Assay Media
Assay plates consisted of M63 salts (2 g/l (NH4)2SO4, 13.6 g/l
KH2PO4, 0.5 mg/l FeSO4 7H2O), supplemented with 0.2%
glucose, 0.01% casamino acids, 1 mM MgSO4, 1.5 mM thiamine,
1.5% bacto-agar (BD). Type I assay plates are further supplemented
with 40 ng/ml anhydrotetracycline to induce tetA expression
without affecting growth rate. Type II assay plates include
,100 ng/ml doxycycline, which both induces tetA expression and
confers ,10% growth advantage to the resistant strain. Varying the
doxycycline concentration roughly 2-fold affected the background
ratios of the strains and the sensitivity of the measurement, but did
not change the patterns of selection observed.
Chemicals
Antibiotic stock solutions were prepared as follows: doxycycline
hyclate (Sigma D-9891, 20 mg/ml in DMSO), erythromycin (Fluka
45673, 20 mg/ml in DMSO), fusaric Acid (Fluka 48205, 15 mg/ml
in DMSO), ciprofloxacin (Fluka 17850, 0.015 mg/ml in 15 mM
HCl), anhydrotetracycline (Acros AC23313, 0.2 mg/ml in EtOH).
Assay for selection
Aliquot stocks of overnight stationary cultures (,10
9 cfu/ml) of
assay strains, grown without antibiotic, are stored at 280uC.Stocksof
a sensitive and resistant assay pair (one expressing CFP and one YFP)
are thawed to room temperature, diluted 100-fold into PBS, and
mixed. 100–200 ml of this mixture is then spread over the surface of
each assay plate and allowed to dry. If assaying pure compounds,a 2–
3 ml drop of each test compound is then spotted onto the agar surface
and allowed to dry. The plates are then incubated at 30C for
20 hours, and then imaged for CFP and YFP signal.
Fluorescent plate imager
Assay plates are imaged in CFP, YFP and white light channels
using a custom, automated plate imager (Figure S3). Exciting
illumination is provided by collimated light from filtered (Chroma,
CFP:D436/20X, YFP:HQ500/20X) high intensity LEDs (www.
luxeonstar.com, CFP: Royal Blue lambertian Luxeon V star, YFP:
Cyan lambertian Luxeon V star). Emitted light is filtered
(Chroma, CFP:D480/30 m, YFP:HQ535/30 m) and captured
by a digital camera (Olympus SP-350, Cam2Com). Custom
software (AutoIt) commands image acquisition, and switches lamps
and filters using an automated filter wheel (Thorlabs FW102B)
mated to a modified rotary switch (Allied Electronics). Images are
automatically analyzed using custom software (MATLAB).
Image analysis
Images of the plates in each fluorescence channel are divided by
images of uniform fluorescent sheets to correct for fluorescence
shading artifacts. Image regions (50650 pixel) representing areas of
no growth (black region) and test compound-free background growth
(yellow region) are manually specified. The intensity data for each
fluorescent channel are then linearly rescaled to give ,1% and 55%
signalsaturationatthespecifiedyellowandblackregionsrespectively.
These normalized images are displayed as the red (resistant strain)
and green (sensitive strain) channels of a false color image.
Soil isolation
Cells were extracted from soil samples by vortexing ,1 g soil
with 5 ml PBS, plating dilutions on a variety of solid media (Potato
Dextrose Agar, Yeast Malt Agar (ISP-2), Inorganic Salts Starch
Agar (ISP-4), Bennett’s Agar, Luria-Bertani Agar (LB), Dilute
Nutrient Agar (DNB)), and incubating for 1–2 weeks at room
temperature. To complete isolation for plug-based assay or
storage, individual colonies were picked from these extract plates,
and re-struck in isolation. Strains were stored in PBS containing
25% glycerol, mixing, and freezing at 280uC.
Overlay Assay
The ‘Overlay’ assay operates on the principle that gradients of
excreted selective compounds are formed around colonies of their
producers, and that such compounds diffuse as gradients into thin
layers of agar containing assay strains which are laid over them. The
assay is performed on 1–2 week-old soil extract plates typically
bearing 15–50 medium-to-large colonies of different strains. 5 ml of
molten Assay Top Agar (identicalto assay agar, but containing 0.75%
agar, 0.4% glucose, 0.02% casamino acids and 300 ng/ml
doxycycline hyclate) at 40uC is mixed with a 50 ml thawed aliquot
(,5610
7 cells per plate) of each strain of an assay pair, poured
uniformly over the surface of a pre-warmed isolation plate, and
allowed to solidify. The plate is then incubated for 20 hours at 30uC
priortoimaging.Imageanalysisisperformedasdescribedabove,and
soil extract colonies with distinctz o n e so fs e l e c t i o na r o u n dt h e m
(green rings) are picked through the overlay and re-struck to isolation.
Plug Assay
5 mm plugs of agar, conditioned by individual isolates for 1–2
weeks, are removed from the plates and replaced into 5 mm holes
punched in standard assay plates spread with assay strain pairs.
The plates are incubated for 20 hours at 30uC, imaged and
analyzed as described above. Plugs from plates conditioned by
control strains known to produce tetracyclines or fusaric acid yield
results similar to the pure compounds (Figure S2).
Screen for microbial producers of selection modulating
compounds
Plug and overlay assays were applied to screen for natural
isolates that modify selection of tetracycline resistance using a
Type II assay (,700 by plug assay; ,60 plates of about 50
colonies each using the overlay assay). We identified and isolated
30 colonies showing clear zone of selections either for or against
resistance. Using Type I and Type II plug assays, compounds
produced by the isolates were identified as selecting either directly
or via potentiated selection on tetracycline resistance (Figure 2).
Supporting Information
Figure S1 Cell-ratio measurements from two-color
fluorescence imaging agree quantitatively with ratios
of labeled E.coli in spot gradients. CFP and YFP-labeled E.
coli, mixed in different ratios, were inoculated onto M63 Glucose
minimal agar (,10
5 cells/spot), grown overnight, and imaged
(Merged fluorescent images, right panels). The images were
Screen for Selection Inverters
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80X80 pixel regions within the mixed colonies (Red squares, right
panels). Using a linear fluorescence/cell assumption and average
signals from the selected regions and the background, we calculate
background autofluorescence, CFP/YFP signal crosstalk, and the
fraction of YFP-labeled cells per spot. Calculated fractions of YFP-
labeled cells reproducibly reflect the inoculated fractions.
(TIF)
Figure S2 Agar plugs conditioned by microbial produc-
ers of selection-modulating compounds give rise to
similar zones of selection as pure compounds. (A)A n
agar plug (Yeast Malt media) conditioned by Streptomyces rimosus
(Oxytetracycline producer) generates a zone of selection for
tetracycline resistance similar to the effect of pure doxycyline (red
rings). (B) An agar plug (Potato Dextrose media) conditioned by
Giberella fujikuroi (fusaric acid producer) generates a zone of
selection against tetracycline resistance, similar to the effect of
pure fusaric Acid (green rings). Type II assays using tetracycline
resistant (YFP, red, tetA efflux pump) and sensitive (CFP, green)
E.coli.
(TIF)
Figure S3 The assay for selection is readily adapted to a
high-throughput screening format. (A,B) Linear diffusion
along channel-wells in a custom plate (B) increases the spatial
density of the assay compared to circular diffusion (A). Zones of
selection for/against resistance appear as red/green bands rather
than circles (compare blue frames). (C) Automated image analysis
yields final ratios between sensitive and resistant strains along each
well. The corresponding compounds are thus classified as selecting
for resistance (red traces), against resistance (green traces), or as
neutral (yellow traces). (D) Custom multicolor fluorescence imager.
(E) Custom 2x24 channel-well assay plates allow integration with
standard 384-well format chemical libraries.
(TIF)
Figure S4 2x24 channel-well linear diffusion plate, in
standard microplate dimensions. For CAD specifications,
see Drawing S1.
(TIF)
Figure S5 Strains for assaying selection on resistance to
four different antibiotics. Fluorescent plate images of different
fluorescently-labeled sensitive (green, YFP-labeled) and antibiotic-
resistant (red, CFP-labeled) assay strains in the presence of four
antibiotics. Strains are differentially resistant to chloramphenicol
(Chl), erythromycin (Ery), neomycin (Neo), and tetracycline (Tet),
and comprise both Gram-negative (E.coli) and Gram-positive
(B.subtilis) bacteria. Red rings along the main diagonal show
classical selection for resistance. Dye swaps yield identical results
(not shown).
(TIF)
Figure S6 The assay for selection provides an efficient
means of identifying compounds that select for human
over plasmodium dihydrofolate reductase. Infection
chemotherapeutics requires windows of drug concentration where
molecular targets in the pathogen are preferentially inhibited while
patient isoforms are left unmolested. By assaying for relative
selection using fluorescently-labeled E.coli which are dependent on
dihydrofolate reductase (DHFR) of either human (YFP-labeled
strain Hky, green) or plasmodium falciparum (CFP-labeled strain
P(0)c, red) origin [1,2,3], we sensitively and directly identify
compounds which preferentially inhibit the pathogen target
isoform. While a non-discriminatory drug (kanamycin, KAN)
inhibits both strains equally, a known anti-malarial DHFR
inhibitor (pyrimethamine, PYR) creates a zone of selection,
indicating a range of concentrations of strong selection for the
human over plasmodium-derived DHFR (Green ring). Native
bacterial DHFR activity is chemically removed by 1 mg/ml
Trimethoprim in the agar [3]. 1.RDjapa LY, Basco LK, Zelikson
R, Rosowsky A, Djaman JA, et al. (2007) Antifolate screening
using yeast expressing Plasmodium vivax dihydrofolate reductase
and in vitro drug susceptibility assay for Plasmodium falciparum.
Molecular and Biochemical Parasitology 156: 89-92. 2.RGerum
AB, Ulmer JE, Jacobus DP, Jensen NP, Sherman DR, et al. (2002)
Novel Saccharomyces cerevisiae screen identifies WR99210
analogues that inhibit Mycobacterium tuberculosis dihydrofolate
reductase. Antimicrobial Agents and Chemotherapy 46: 3362-
3369. 3.RLozovsky ER, Chookajorn T, Brown KM, Imwong M,
Shaw PJ, et al. (2009) Stepwise acquisition of pyrimethamine
resistance in the malaria parasite. Proc Natl Acad Sci U S A 106:
12025-12030.
(TIF)
Table S1 List of strains and plasmids.
(PDF)
Methods S1 Supplementary methods for high-through-
put screening using 2x24 channel-well plates and
screening for differential inhibition of human and
plasmodium dihydrofolate reductase.
(PDF)
Drawing S1 Technical CAD drawing (.dxf) of 2624
channel-well linear diffusion plates.
(DXF)
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